Oxymetholon 50mg/tab 100 Tabletten by Dragon-Pharma

Usage

1. Assess your AR sensitivity baseline before starting: users returning from a recent cycle within eight weeks should postpone to allow full receptor density restoration.
2. Take each tablet orally with a full glass of water; consistent timing relative to meals improves absorption predictability and supports stable plasma levels relevant to receptor occupancy.
3. Begin at one tablet (50 mg) daily in week one to occupy receptors without triggering aggressive downregulation in the opening phase.
4. Advance to two tablets (100 mg) daily from week two through week four, recognising that this is the window of maximal AR responsiveness — training intensity should peak here.
5. If extending beyond four weeks, reduce back to one tablet (50 mg) daily as a deliberate step-down to reduce the rate of ongoing receptor desensitization before cycle end.
6. Initiate PCT within 24–48 hours of the final tablet to support endogenous hormonal recovery while waiting for AR density to normalise — do not begin a new Oxymetholone cycle until both endocrine recovery and receptor re-sensitisation intervals have elapsed.

Warnings

Frequently asked questions

Does the body actually develop tolerance to Oxymetholone during a cycle?

Yes — and the mechanism is receptor-level, not merely systemic adaptation. Sustained supraphysiological androgen concentrations trigger compensatory downregulation of androgen receptor density in skeletal muscle tissue, a process documented by saturation-binding analyses on biopsy samples. As AR density falls, the anabolic signal produced per milligram of Oxymetholone decreases, even if plasma levels remain stable — which is why gains typically plateau well before the four- to six-week mark.

What exactly is androgen receptor desensitization and how does it differ from general tolerance?

Androgen receptor desensitization is a specific molecular event: prolonged AR occupation by a high-affinity ligand induces a reduction in receptor number and co-activator recruitment efficiency at the nuclear membrane, measurable via ligand-competition radioassay methodology. General pharmacological tolerance can involve many adaptive mechanisms; AR desensitization is a precise, tissue-level process in skeletal muscle that directly reduces the transcriptional output driving hypertrophy — it is not a vague 'getting used to' effect.

How long should the off-cycle break be to fully restore androgen receptor sensitivity after Oxymetholone use?

Immunohistochemistry-based receptor re-expression studies place full AR density recovery at approximately four to eight weeks post-cessation, with the exact duration dependent on prior dose magnitude and cycle length. A four-week Oxymetholone cycle will generally require a shorter recovery interval than a six-week cycle at maximum dose. Attempting to restart before receptor density has normalised simply means the new cycle begins at a pharmacologically compromised baseline.

How does Dragon-Pharma's 50mg tablet strength help manage receptor desensitization compared to lower-dose formats?

The 50 mg per tablet concentration — the highest in this product class — allows a clean step-down protocol in the final week or two of a cycle without requiring tablet splitting, which can introduce dosing inaccuracies. A controlled taper reduces the abruptness of AR stimulus removal, potentially supporting a more orderly receptor re-sensitisation process. Lower per-tablet concentrations require multiple tablets to reach equivalent doses, adding variables to each serving.

Are Dragon-Pharma's Oxymetholone tablets supplied in blisters or a jar, and can they be split for dose adjustment?

Dragon-Pharma packages Oxymetholone 50mg in a 100-tablet format within a secure container, with each tablet being a uniform compressed oral solid dose. While tablets can physically be divided for fine-tuned dosing during a step-down phase, relying on HPLC-verified content uniformity — confirmed at batch level — means that even a half-tablet delivers a predictable fraction of the stated 50 mg, making dose titration considerably more reliable than with unverified generic products. (2) angle_used

Manufacturer

Dragon-Pharma's Oxymetholone 50mg tablets reach the end user only after clearing a release sequence that starts well before compression. Incoming Oxymetholone API is quarantined on receipt, subjected to identity confirmation and purity characterisation, and released to the formulation floor exclusively upon passing internal specification — a pre-compression gate that filters out any out-of-specification raw material before it can influence finished-tablet potency. Once the compression stage produces the finished 50 mg tablets, a statistically derived sample from each lot is pulled and quantified by HPLC against a certified Oxymetholone reference standard; the resulting potency figure is recorded on the batch certificate and is what backs the declared label claim. Separately, each lot clears LAL (Limulus Amebocyte Lysate) endotoxin testing — a quality step that applies equally to the oral solid-dose format as to injectable presentations within Dragon-Pharma's portfolio. The 100-tablet container itself is part of the presentation strategy: primary packaging is selected to protect tablet integrity against humidity and mechanical stress during transit, ensuring the dissolution profile verified at manufacture is maintained through to the point of use.